Phase III
Eiger BioPharmaceuticals announced that its COVID-19 therapeutic, Peginterferon Lambda reduced the risk of hospitalization and emergency room visits by 50%.
This is the first approval for the drug in gastroenterology and was based on data from three Phase III trials.
The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen’s Multiple Sclerosis (MS) drug, Tecfidera.
AstraZeneca and Merck announced their Lynparza drug reduced the risk of death by 32% compared to placebo for specific breast cancer patients.
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
After reviewing the trial’s Independent Data Monitoring Committee, the EMPA-KIDNEY trial announced it would stop early as it met prespecified criteria for positive efficacy.
Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
PRESS RELEASES